Crisis Capital Snapshot: Impact on Private Biotech Financing
This article was originally published in Start Up
Executive Summary
According to data from FDC-Windhover's Strategic Transactions, during the five full months since the beginning of the current crisis (September 2008 through January 2009), private biopharma companies raised $1,657 million across 94 deals. In the same time-frame last year that same cohort did 112 transactions and raised $2,187 million. In short, total funding has declined roughly 24% from one period to the next.